The abstract is read at the publisher; the summary is JClub's.
Intranasal VIP-N+circRNA vaccination in mice encoding RSV pre-F elicits the strongest neutralizing activity and cross-protection against RSV-A and RSV-B, significantly reducing pulmonary viral burden and lung inflammation.
- Why it matters: RSV causes acute lower respiratory tract disease, and current vaccines often fail to generate strong respiratory mucosal immunity needed for protection at the infection site.
- What they did: The study built a receptor-guided intranasal circRNA platform using a vasoactive intestinal peptide–nucleocapsid fusion (VIP-N) to deliver circRNA encoding RSV antigens, testing immune outcomes after intranasal versus intramuscular dosing in mice.
- The result: VIP-N+circRNA vaccines induced serum IgG comparable to intramuscular delivery, uniquely promoted bronchoalveolar lavage IgA, increased T follicular helper 1 cells, and skewed responses toward Th1 without increased Th2 cytokines linked to vaccine-enhanced respiratory disease.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.